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Aims: The aim of this report from a general population sample was to examine the
association of respiratory symptoms and COPD severity with HRQoL (health related quality
of life).
Methods: In a general population study in 1996–1997, of 3181 invited subjects aged 26–81
years, a total of 2405 returned postal questionnaires on respiratory symptoms and
attended a clinical examination. Altogether 2306 subjects completed the SF-12
questionnaire, a general HRQoL questionnaire. The univariate relationships between
respiratory symptom burden, degree of bronchial obstruction, and HRQoL were
investigated by the Wilcoxon test for trend and the Mann–Whitney U-test. Adjustment
for gender, age, education, and smoking habits was done using linear regression with
estimation of robust standard errors.
Results: In asymptomatic subjects the mean (SD) physical component scale (PCS) score
was 51.8 (7.4) and the mean (SD) mental component scale (MCS) score was 52.6 (8.0).
Having one to six symptoms gave mean (SD) PCS scores of 49.6 (8.8), 48.2 (9.7), 45.1
(10.4), 42.1 (11.9), 38.1 (11.4), and 34.7 (10.2), respectively. The corresponding numbers
for MCS scores were 50.9 (8.0), 48.8 (9.6), 48.9 (10.6), 47.2 (10.2), 43.6 (10.4), and 44.2
(9.8), respectively. In the multivariate model, subjects in GOLD stages 3 and 4 had
significantly reduced PCS scores, while subjects with COPD had a significantly higher MCS
score than subjects without COPD, after adjustment for symptoms. Both the PCS and MCS
scores declined significantly with increasing number of respiratory symptoms.Elsevier Ltd. All rights reserved.
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M. Voll-Aanerud et al.400Conclusion: In a general population sample, the burden of respiratory symptoms is more
strongly associated with generic HRQoL than is lung function.
& 2007 Elsevier Ltd. All rights reserved.Introduction
According to the World Health Organization (WHO), 80
million people have moderate to severe chronic obstructive
pulmonary disease (COPD) worldwide, and 3 million people
died from COPD in 2005.1 No treatment to date save smoking
cessation has proved to slow the deterioration of lung
function. Thus, the objectives of treatment have been to
decrease the burden of the disease through relief of
symptoms, improvement of exercise tolerance, and preven-
tion and treatment of exacerbations.
Health related quality of life (HRQoL) has become an
important outcome measure of treatment in COPD patients.
Although most studies find that HRQoL is impaired in
patients with severe COPD,2–6 findings differ with lesser
degrees of reduction in FEV1.
3,7 Three previous studies have
found respiratory symptoms to be more closely related to
HRQoL than impairment in FEV1.
8–10 This could indicate that
HRQoL is impacted more by symptoms than the actual
airway narrowing that FEV1 measures. All these studies have
been performed on patient specific populations. Such
studies may be biased, since patients are usually recruited
from in- or outpatients clinics, and may have more impaired
HRQoL than patients who do not attend a clinic regularly.
Respiratory symptoms are experienced not only by COPD
patients, but also by subjects with no specific respiratory
disease.
To evaluate the impact of respiratory symptoms on
HRQoL, we wanted to assess HRQoL both in healthy subjects
and subjects with spirometrically confirmed COPD. To our
knowledge no such data are published from the population
at large. Thus, the aim of this report from a general
population sample was to examine the association of
respiratory symptoms and COPD severity with HRQoL.Methods and materials
Study population
The present study was based on participants in the second
phase of the Hordaland County Cohort Study, performed in
1996–1997. The first phase was conducted in 1985, where
3786 subjects aged 15–70 were randomly sampled from
Bergen and 11 surrounding municipalities; 3370 responded.
Information on sampling procedures and data collection in
this longitudinal study have been reported previously.11 In
1996–1997, 189 subjects were deceased, leaving 3181
eligible for the second phase. A total of 2819 (89%) answered
a postal respiratory symptom questionnaire that included
questions on smoking habits and educational level. The
respondents were invited to a research purpose clinical
examination of which 2401 (75%) attended. The examination
included post-bronchodilator spirometry and completion of
the SF-12 questionnaire on HRQoL. Altogether 2306 subjectshad complete data for the SF-12 questionnaire and were
entered into the analyses. The study was approved by the
Regional Committee of Medical Research Ethics. Informed
consent was obtained from each participant prior to the
survey.
The questionnaires
Information on respiratory symptoms was obtained through
the postal questionnaire. The wording of the symptoms is
given in the appendix. The six symptoms were morning
cough, chronic cough, phlegm cough, wheeze, dyspnoea
attacks, and dyspnoea grade 2. The questions have been
validated against lung function and bronchial reactivity12,13
and compared with the British Medical Research Council
respiratory questionnaire on chronic bronchitis.14 The six
symptoms were combined into one categorical variable, so
that 0 corresponds to no symptoms and 6 corresponds to
presence of all six symptoms. The SF-12 questionnaire is a
12-item general quality of life questionnaire previously
validated,15 and widely used in both general populations16
and populations with chronic respiratory diseases.4,17 The
SF-12 measures quality of life in the physical component
score (PCS), and the mental component score (MCS).18 The
SF-12 was scored using the U.S. algorithms given in the SF-12
manual,18 where a value of 50 equals the mean score and 10
is the standard deviation for both the PCS and MCS in the
American normal population. A high score indicates better
HRQoL and the scores range between 10 and 70.
Smoking habits, educational level, and body mass
index
Smoking habits were categorized as never-, ex- and current
smoking. Current smoking was further categorized by
average daily cigarette consumption; 1–9, 10–19, and 20
or more.
Educational level was divided into three categories: up to
9 years of schooling (primary), a degree requiring 12 years of
schooling (secondary), and higher education (university).19
Body mass index (weight in kilograms divided by height in
metre squared, kg/m2) was categorized according to World
Health organization20: Underweight (and o18.5 kg/m2),
normal weight (18.5–24.9kg/m2), overweight (25–29.9kg/m2),
and obese (430kg/m2).
Spirometry
Spirometry was measured with Gould 2100 pulmonary
function equipment21 according to the American Thoracic
Society (ATS) criteria, 15min after inhalation of 0.3mg
powdered salbutamol from a Turbohaler (AstraZeneca AS,
Ska˚rer, Norway). COPD was defined as a FEV1/FVC ratio and
o0.70.22 FEV1 as percentage predicted was used to assess
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population were used in assessing post-bronchodilator
predicted values of FEV1.
23 We used the GOLD classification
of disease severity22,24: mild COPD as FEV1480%, moderate
COPD as FEV1 from 50% to 80%, severe COPD as FEV1 from
30% to 50%, and very severe as FEV1 and o30%. Since there
were few patients in the severe and very severe categories,
these were grouped together.
Statistical analyses
The statistical software Stata version 8.0 was used for the
statistical analyses.25 Categorical variables were described
by frequency distributions and tables and continuous
variables by means and standard deviations in subgroups of
the sample for each gender. Univariate relationships
between SF-12 scores and the stages of COPD and number
of respiratory symptoms were examined by the Wilcoxon
test for trend. The univariate relationships between the SF-
12 scores and the individual respiratory symptoms were
examined by the Mann–Whitney U-test. The multivariate
relationship between the SF-12 scores and the explanatory
variables were examined in linear regression models. Robust
variance estimation using the Huber–White sandwich esti-
mator of variance was used in these models due to the
skewed distributions of some SF-12 summary scores,26 that
may imply a deviation from standard assumptions.25
Results
Demographic characteristics are given in Table 1.
The prevalence of never smokers was higher among
women than men, and there were fewer ex smoking women
than ex-smoking men. Among smokers, men had on average
a higher daily consumption. More men (9.8%) than women
(3.2%) had COPD according to the GOLD criteria. Dyspnoea
grade two was more prevalent among women than men.
More than 45% of the population did not have any respiratory
symptom, almost one-fourth of both women and men had
one symptom, whereas almost 2% of the population had all
six respiratory symptoms.
The univariate relationships between the PCS and MCS,
symptoms and COPD according to the GOLD classification,
are given in Table 2. Dyspnoea grade 2 was the symptom
with the lowest mean PCS; dyspnoea attacks had the lowest
mean MCS. Both scores decreased significantly with increas-
ing number of symptoms, but more so for physical than for
mental scores. The PCS also fell with increasing COPD
severity, in contrast to the MCS.
In Table 3, the results of robust linear regressions are
presented with the individual respiratory symptoms, number
of respiratory symptoms, and disease severity as explana-
tory variables in three separate regression models, all
adjusted for gender, age, education, smoking, and body
mass index. Each individual respiratory symptom was a
significant explanatory variable for the PCS. The PCS
decreased with increasing number of symptoms. Number
of symptoms explained 25% of the variance in the PCS
(R2 0.247). The PCS was significantly lower in patients with
COPD in GOLD stages 3 and 4 compared to GOLD stages 1, 2,
and subjects without COPD. The individual respiratorysymptoms were significantly associated with reduced MCS.
Like the PCS, the MCS declined with increasing number of
symptoms. However, the MCS did not vary significantly with
COPD severity according to the GOLD classification.
Figure 1 shows the results of robust linear regressions for
PCS and MCS by both number of respiratory symptoms and
GOLD classification in the same model, adjusted for gender,
age, education, smoking and body mass index. Presence of
one or more respiratory symptoms was related to impair-
ment in the physical score, and the more symptoms, the
lower the physical score. COPD was related to lower PCS,
but only for GOLD stages 3 and 4. The MCS was significantly
lower if respiratory symptoms were present, but the
differences were smaller than for the PCS.
After adjustments, the MCS was significantly higher in
subjects with COPD than without.
The decline in the PCS and MCS by increasing number of
symptoms was examined both in subjects with and without
COPD. The negative effect of an increasing number of
symptoms on both PCS and MCS was similar regardless of
whether subjects had COPD or not.Discussion
In this general population sample, both the physical and
mental quality of life scores were more strongly related to
respiratory symptoms than severity of COPD as defined by
the GOLD classification. Both the PCS and the MCS decreased
significantly with an increasing number of symptoms. The
PCS also decreased with increasing severity of COPD, even
after adjusting for gender, age education, smoking, and
body mass index. After additional adjustment for respiratory
symptoms, the MCS actually increased with increasing
severity of COPD.
To our knowledge, this is the first study that evaluates the
relationship between HRQoL, severity of COPD, and respira-
tory symptoms in a general population sample including both
healthy subjects and subjects with COPD. The strengths of
this study are the wide age span, high response rate, and the
use of post-bronchodilator reference values in the calcula-
tion of FEV1 percent predicted. The latter reduces the risk
of misclassification of asthmatic subjects, with reversible
airway obstruction, as COPD cases. The limitations of the
study should also be acknowledged. Firstly, the cross
sectional nature of the study prevents presumptions of
causality. Whether HRQoL deteriorates after the symptoms
have arisen or the reduced HRQoL is a precursor for the
detection of symptoms cannot be determined. Secondly, the
data were obtained from subjects attending a clinical
examination. The possibility that subjects with poor health
were less able to attend might have biased the results.
However, the respondents were representative of those
invited by gender, age and smoking habits.11 The fact that
the participants showed up in person enabled us to have a
nurse checking the questionnaires for completion and asking
the participants to fill in unanswered questions. As such we
obtained a completion rate of 96% as compared to a rate of
67% obtained in the SF-36 survey in Norway in 1998.27
Thirdly, we lack data on comorbidity. There are studies that
report lower HRQoL in COPD patients with concomitant
conditions.2,7 One of the reasons why dyspnoea had a larger
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Table 1 Description of the study population.
Women Men p
n % n %
Age (yr)
Mean (SD) 1193 50.6 (15.3) 1113 48.8 (14.4) 0.003
Educational levely (%)
Primary 233 19.5 183 16.4 0.086z
Secondary 682 57.2 641 57.6
University 258 21.6 276 24.8
Smoking habitsy (%) o0.001z
Never smokers 548 46.1 363 32.8
Ex-smokers 275 23.1 364 32.9
Current smokers
1–9 cigarettes/day 96 8.1 58 5.2
10–19 cigarettes/day 212 17.8 197 17.8
420 cigarettes/day 59 5.0 124 11.2
Body mass index
Underweight 13 1.1 10 0.9 o0.001z
Normal weight 640 53.7 459 41.2
Overweight 361 30.3 521 46.8
Obese 168 14.1 120 10.8
Respiratory symptoms (%) z
Morning cough 305 25.6 278 25.0 0.745
Chronic cough 151 12.7 137 12.3 0.801
Phlegm cough 258 21.6 296 26.6 0.005
Wheeze 278 23.3 251 22.6 0.899
Dyspnoea attacks 205 17.2 144 12.9 0.004
Dyspnoea grade 2 244 20.5 134 12.0 o0.001
Number of respiratory symptoms (%) 0.338z
0 557 46.7 532 47.8
1 250 21.0 236 21.2
2 157 13.2 156 14.0
3 99 8.3 89 8.0
4 63 5.3 64 5.8
5 40 3.4 19 1.7
6 20 1.7 11 1.0
COPDJ (%) o0.001z
Stage 1 12 1.0 40 3.6
Stage 2 23 1.9 54 4.9
Stages 3 and 4 4 0.3 14 1.3
Difference tested with t-test.
y33 subjects had unknown educational level.
zDifference tested with w2 test.
y10 subjects had unknown smoking habits.
zDifference tested with rank sum test.
J159 subjects did not do spirometry. Stages based on the GOLD criteria.
M. Voll-Aanerud et al.402impact on the PCS and MCS than the other symptoms may be
that dyspnoea can be related to other conditions such as
heart disease.
The choice of a generic questionnaire only in the
assessment of HRQoL, lung function, and respiratory
symptoms might also be questioned. A disease specific tool
such as the St. George’s respiratory questionnaire28 might bemore sensitive to HRQoL in patients with chronic respiratory
disease, but the sensitivity is weak when applied in healthy
subjects or in subjects not aware of having respiratory
disease. According to recent literature,29 there is a high
proportion of undiagnosed COPD subjects in the general
population. Thus, using a generic questionnaire was most
appropriate when we assessed HRQoL in this population.
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Table 2 The physical- (PCS) and mental- (MCS) component scores by respiratory symptoms.
PCS p MCS p
Mean (SD) Mean (SD)
Respiratory symptoms
Morning cough 45.6 (10.9)  48.5 (9.8) 
Chronic cough 43.6 (11.6)  46.8 (10.9) 
Phlegm cough 46.2 (10.8)  48.6 (10.0) 
Wheeze 46.1 (10.6)  48.5 (9.9) 
Dyspnoea attacks 43.1 (11.9)  47.1 (9.9) 
Dyspnoea grade 2 39.7 (11.9)  47.3 (10.1) 
Number of respiratory symptomsy  
0 51.8 (7.4) 52.6 (8.0)
1 49.6 (8.8) 50.9 (8.5)
2 48.2 (9.7) 48.8 (9.6)
3 45.1 (10.4) 48.9 (10.6)
4 42.1 (11.9) 47.2 (10.2)
5 38.1 (11.4) 43.5 (10.4)
6 34.7 (10.2) 44.2 (9.8)
No COPDy 49.6 (9.1)  50.8 (9.0) ns
COPD
Stage 1 49.5 (7.8) 52.9 (7.3)
Stage 2 43.8 (10.9) 51.7 (9.1)
Stages 3 and 4 36.2 (11.5) 53.8 (8.1)
*po0.001.
Significance tested with Mann–Whitney U-test.
ySignificance tested with Wilcoxon rank sum test for trend.
Respiratory symptoms, COPD severity, and health 403In a population-based study of HRQoL in 168 COPD
subjects in Sweden,6 there was no significant relationship
between the MCS of the SF-36 questionnaire and COPD
disease severity, neither classified according to the British
Thoracic Society (BTS) nor the GOLD criteria. Our finding
that MCS did not decline by increasing COPD severity, but
possibly increased, contradicts the findings of a recent
study4 observing a reduction in mental quality of life scores
by increasing COPD levels. The study by Carrasco Garrido et
al.4 was conducted on a substantial number of patients
(n ¼ 10 711), but there may be at least two explanations for
the discrepancy between that and the present study. Firstly,
their study population was recruited from health centres,
patient lists and medical records. People seeking medical
care are likely to have more comorbid conditions or other
complaints that may influence HRQoL negatively compared
with a random sample of the general population. Secondly,
the population was older compared to our study. In many
studies, quality of life has been shown to decline with age.27
Apart from methodological differences it is possible that the
SF-12 questionnaire is less sensitive to mental health in a
community study. However, this is contradicted by several
studies in which the SF-12 was sensitive to mental
distress.30,31 It could also be that there is actually no
relationship between the mental quality of life and COPD
severity by GOLD definition in a community setting. Several
factors could support this interpretation. Firstly, the GOLD
severity classification is based solely on FEV1. Examinations
of postmortem and surgical lung specimens, as well asradiographic studies, have shown that FEV1 is insensitive to
anatomic disease severity.32,33 The multidimensional index
BODE that includes the body mass index (B), percentage of
predicted FEV1 (O), dyspnoea (D), and the 6-min walking
distance test (E), predicts mortality better than FEV1.
34
Hence, FEV1 provides far from a complete picture of COPD.
Finally, our findings could result from lowered expectations
of health. Chronically ill patients tend to adapt to
irreversible changes in their health through lower expecta-
tions to HRQoL.35 Their experience of quality of life might
be lower than among healthy people, but due to the reduced
expectations they are in some sort of quality of life
equilibrium.
Some recent studies address mental health and
COPD.9,36,37 Schlecht et al.9 found dyspnoea scores, but
not spirometric values, to be associated with indices of
anxiety, depression and neuroticism. Studies on American
veterans have observed a relationship between anxiety,
depression and COPD severity.36,37 However, these surveys
were all based on highly selected populations. There is
reason to believe that veterans have a higher prevalence of
both anxiety and depression than the normal population.
The observed relationship between COPD severity and
lower physical scores was in large part due to subjects with
severe and very severe disease (Table 3). These findings
are supported by those of Miravitlles et al.7 who found
that having FEV1o50% predicted was related to lower
HRQoL measured by the St. George’s Respiratory Question-
naire (SGRQ).
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Table 3 Robust linear regressions with the physical and mental component scores as dependent variables by respiratory
symptoms, by number of respiratory symptoms, and by COPD severity, respectively.
PCS p MCS p
R2 Coeff. (SE) R2 Coeff. (SE)
Respiratory symptoms
Morning cough 0.159 3.7 (0.5) * 0.048 2.5 (0.5) *
Chronic cough 0.166 5.4 (0.7) * 0.054 3.9 (0.7) *
Phlegm cough 0.155 3.4 (0.5) * 0.048 2.5 (0.5) *
Wheeze 0.158 3.8 (0.5) * 0.045 2.2 (0.5) *
Dyspnoea attacks 0.19 6.4 (0.6) * 0.056 3.7 (0.6) *
Dyspnoea grade 2 0.258 9.6 (0.6) * 0.061 4.1 (0.6) *
Number of respiratory symptomsy
0 0.244  0.081 – –
1 2.1 (0.4) * 1.5 (0.5) **
2 3.1 (0.6) * 3.6 (0.6) *
3 5.8 (0.8) * 3.3 (0.8) *
4 9.3 (1.0) * 5.2 (1.0) *
5 12.6 (1.4) * 8.3 (1.4) *
6 15.2 (1.7) * 7.3 (1.7) *
No COPDz 0.143 – 0.039 – –
COPD
Stage 1 1.3 (1.0) ns 1.5 (1.1) ns
Stage 2 3.1 (1.2) *** 1.0 (1.1) ns
Stages 3 and 4 11.5 (2.7) * 2.4 (1.9) ns
*po0.001; **po0.01; *** po0.05.
All analyses adjusted for gender, age, smoking, and body mass index.
One respiratory symptom at the time included in the model, adjusted for gender, age, education, smoking, and body mass index.
yThe number of respiratory symptoms included in a model, adjusted for gender, age, education, and smoking, and body mass index.
zAdjusted for gender, age, education, smoking, and body mass index.
Figure 1 The results of robust linear regressions with the physical- (PCS) and mental component scores (MCS) as dependent
variables by number of respiratory symptoms and COPD severity included in the same model. Adjusted for gender, age, smoking, and
body mass index.
M. Voll-Aanerud et al.404There is a complex relationship between HRQoL and
functional status. The progression of COPD will lead to
physical deterioration, increase in symptoms during activ-ities of daily living (ADLs), and in return elimination of
ADLs.38 The first ADLs that are eliminated are leisure
activities that require great effort, but might not be crucial
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FEV1o50% it is likely that ADLs more essential to physical
quality of life are eliminated, for instance, ADLs that make a
person independent of daily support from professional
health care.
To our knowledge the present study is the first to examine
the relationship between quality of life and number of
respiratory symptoms. We observed a dose–response rela-
tionship between number of symptoms and impaired levels
of both the PCS and MCS. This relationship was true in
subjects with and without spirometric airflow obstruction.
This adds evidence that symptoms burden is a better marker
for reduced HRQoL than severity of COPD according to the
GOLD classification, at least in a general population.
Spirometry is widely used, not only in diagnosing COPD,
but also in evaluating COPD patients. Asking for the
presence of respiratory symptoms is easy, less costly, and
it describes the well-being of the patient better than the
degree of bronchial obstruction. The fact that increasing
number of symptoms was strongly related to a decrease in
both the PCS and the MCS emphasizes the importance of
symptom assessment when evaluating patients with COPD.
Finally, the current study indicates that the impaired mental
quality of life by increasing COPD severity found in studies
based on cases from in- and outpatient clinics are not
necessarily generalizable to the COPD population at large.
The burden of COPD on the society may be less than
indicated by studies on patient populations.
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Appendix AThe wording of the questions on respiratory symptoms
Do you usually cough or clear your throat in the morning?
[Yes, no]
Do you usually have phlegm when coughing? [Yes, no]
Do you have a cough for three months or more altogether
during a year? [Yes, no]
Are you breathless when you climb two flights of stairs at an
ordinary pace? [Yes, no] (dyspnoea grade 2)
Do you sometimes experience attacks of breathlessness?
[Yes, no]
Have you ever had wheezing in your chest in the last 12
months? [Yes, no]References
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